We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+25.98%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$293M
(+21%)
Cap. Flow
+$59.1M
Cap. Flow
% of AUM
3.53%
Top 10 Holdings %
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5
Avg Time Held
0.9
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$23.2M |
| 2 |
NewAmsterdam Pharma
NAMS
|
+$20.3M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
+$19.6M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$13.3M |
| 5 |
BridgeBio Pharma
BBIO
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$11.6M |
| 2 |
Vaxcyte
PCVX
|
+$11M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$7.67M |
| 4 |
Cogent Biosciences
COGT
|
+$7.55M |
| 5 |
Gritstone bio, Inc. Common Stock
GRTS
|
+$6.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.94% |
| 2 | Miscellaneous | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Enliven Therapeutics
ELVN
$2.92B
| $17M | 1.01% |
830,983
| – | – |
2023 Q1
1 quarter
|
|
27
Oric Pharmaceuticals
ORIC
$1.31B
| $16.6M | 0.99% |
+2,142,855
| New | +$12.2M |
2023 Q2
0 quarters
|
|
28
Trevi Therapeutics
TRVI
$1.73B
| $16.4M | 0.98% |
6,881,090
+217,500
| +3% | +$548K |
2022 Q2
4 quarters
|
|
29
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $15.2M | 0.91% |
265,511
+51,271
| +24% | +$2.68M |
2023 Q1
1 quarter
|
|
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $12.5M | 0.75% |
393,000
| – | – |
2022 Q1
5 quarters
|
|
|
RETA
31
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $10.2M | 0.61% |
+100,430
| New | +$9.5M |
2023 Q2
0 quarters
|
|
32
MacroGenics
MGNX
$215M
| $9.65M | 0.58% |
1,803,204
+100,000
| +6% | +$617K |
2023 Q1
1 quarter
|
|
33
Replimune Group
REPL
$1.11B
| $8.98M | 0.54% |
386,762
-300,000
| -44% | -$5.86M |
2022 Q1
5 quarters
|
|
34
Autolus Therapeutics
AUTL
$460M
| $8.92M | 0.53% |
3,746,857
| – | – |
2022 Q1
5 quarters
|
|
35
Prothena Corp
PRTA
$438M
| $8.73M | 0.52% |
127,900
| – | – |
2022 Q4
2 quarters
|
|
36
Intellia Therapeutics
NTLA
$1.65B
| $8.31M | 0.5% |
203,684
| – | – |
2022 Q1
5 quarters
|
|
37
Arvinas
ARVN
$465M
| $7.08M | 0.42% |
285,331
| – | – |
2022 Q1
5 quarters
|
|
38
Edgewise Therapeutics
EWTX
$4.14B
| $5.8M | 0.35% |
749,022
+66,561
| +10% | +$561K |
2023 Q1
1 quarter
|
|
39
Immunovant
IMVT
$5.69B
| $5.69M | 0.34% |
300,000
-285,759
| -49% | -$5.33M |
2022 Q1
5 quarters
|
|
40
DELISTED
bluebird bio
BLUE
| $5.63M | 0.34% |
85,495
+13,457
| +19% | +$984K |
2022 Q3
3 quarters
|
|
41
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $5.21M | 0.31% |
+370,000
| New | +$5.29M |
2023 Q2
0 quarters
|
|
42
Silence Therapeutics
SLN
$580M
| $4.85M | 0.29% |
881,173
| – | – |
2022 Q1
5 quarters
|
|
|
43
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $4.68M | 0.28% |
2,401,714
-2,760,634
| -53% | -$6.46M |
2022 Q1
5 quarters
|
|
44
Sutro Biopharma
STRO
$189M
| $3.63M | 0.22% |
78,000
-99,648
| -56% | -$4.96M |
2022 Q1
5 quarters
|
|
45
ADC Therapeutics
ADCT
$192M
| $3.54M | 0.21% |
1,647,030
| – | – |
2023 Q1
1 quarter
|
|
46
Aclaris Therapeutics
ACRS
$509M
| $2.74M | 0.16% |
264,377
| – | – |
2022 Q1
5 quarters
|
|
47
Passage Bio
PASG
$11.6M
| $1.74M | 0.1% |
92,500
-95,346
| -51% | -$1.89M |
2022 Q1
5 quarters
|
|
|
48
NewAmsterdam Pharma Warrant
NAMSW
| $1.05M | 0.06% |
500,333
| – | – |
2022 Q4
2 quarters
|
|
49
DELISTED
Allakos
ALLK
| – | – |
-1,112,684
| Closed | -$4.95M | – |
|
|
RNAM
50
DELISTED
Avidity Biosciences
RNAM
| – | – |
-500,000
| Closed | -$7.67M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2023 Portfolio in Review
As of Q2 2023, Frazier Life Sciences Management held 53 positions worth $1.67B, up 21% from $1.38B the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Frazier Life Sciences Management deployed $59.1M of net new capital in Q2 2023, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Disc Medicine: 655,000 shares worth $29.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Vaxcyte, an estimated $11M trimmed.
- Frazier Life Sciences Management's largest Q2 2023 buy was Disc Medicine: 655,000 shares worth $29.1M.
- Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q2 2023, an estimated $20.3M increase.
- Frazier Life Sciences Management's biggest Q2 2023 reduction was Vaxcyte, cutting an estimated $11M.
- Frazier Life Sciences Management fully exited VectivBio Holding AG Ordinary Shares in Q2 2023, selling an estimated $11.6M.
- Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.67B portfolio in Q2 2023.
- Frazier Life Sciences Management opened 4 new positions and closed 5 in Q2 2023.
- Frazier Life Sciences Management's portfolio value rose 21% quarter-over-quarter to $1.67B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2023, filed 14 Aug 2023.